Kana V - Search Results

1

Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects.

Petersen JA, Kuntzer T, Fischer D, von der Hagen M, Huebner A, Kana V, Lobrinus JA, Kress W, Rushing EJ, Sinnreich M, Jung HH. Petersen JA, et al. Among authors: kana v. BMC Neurol. 2015 Oct 6;15:182. doi: 10.1186/s12883-015-0449-3. BMC Neurol. 2015. PMID: 26444858 Free PMC article.

2

Exercise effects in Huntington disease.

Frese S, Petersen JA, Ligon-Auer M, Mueller SM, Mihaylova V, Gehrig SM, Kana V, Rushing EJ, Unterburger E, Kägi G, Burgunder JM, Toigo M, Jung HH. Frese S, et al. Among authors: kana v. J Neurol. 2017 Jan;264(1):32-39. doi: 10.1007/s00415-016-8310-1. Epub 2016 Oct 17. J Neurol. 2017. PMID: 27747393 Free article.

3

Muscle magnetic resonance imaging of the lower limbs: valuable diagnostic tool in the investigation of childhood neuromuscular disorders.

Kana V, Kellenberger CJ, Rushing EJ, Klein A. Kana V, et al. Neuropediatrics. 2014 Oct;45(5):278-88. doi: 10.1055/s-0034-1381954. Epub 2014 Jul 15. Neuropediatrics. 2014. PMID: 25025777

4

Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy.

Martin F, Kana V, Mori AC, Fischer D, Parkin N, Boltshauser E, Rushing EJ, Klein A. Martin F, et al. Among authors: kana v. Eur J Pediatr. 2014 Dec;173(12):1691-4. doi: 10.1007/s00431-014-2314-6. Epub 2014 Apr 8. Eur J Pediatr. 2014. PMID: 24706162

5

Teaching NeuroImages: Recurrent oculomotor palsies caused by neurosarcoidosis.

Kana V, Petersen JA, Ikenberg K, Chappaz A, Gerth-Kahlert C, Appenzeller P, Linnebank M. Kana V, et al. Neurology. 2016 Jul 19;87(3):e31-2. doi: 10.1212/WNL.0000000000002865. Neurology. 2016. PMID: 27432184 Free article. No abstract available.

6

Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy.

Stenzel W, Preuße C, Allenbach Y, Pehl D, Junckerstorff R, Heppner FL, Nolte K, Aronica E, Kana V, Rushing E, Schneider U, Claeys KG, Benveniste O, Weis J, Goebel HH. Stenzel W, et al. Among authors: kana v. Neurology. 2015 Mar 31;84(13):1346-54. doi: 10.1212/WNL.0000000000001422. Epub 2015 Mar 6. Neurology. 2015. PMID: 25746564 Free article.

7

Cystatin F is a biomarker of prion pathogenesis in mice.

Nuvolone M, Schmid N, Miele G, Sorce S, Moos R, Schori C, Beerli RR, Bauer M, Saudan P, Dietmeier K, Lachmann I, Linnebank M, Martin R, Kallweit U, Kana V, Rushing EJ, Budka H, Aguzzi A. Nuvolone M, et al. Among authors: kana v. PLoS One. 2017 Feb 8;12(2):e0171923. doi: 10.1371/journal.pone.0171923. eCollection 2017. PLoS One. 2017. PMID: 28178353 Free PMC article.

8

Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling.

Nuvolone M, Paolucci M, Sorce S, Kana V, Moos R, Matozaki T, Aguzzi A. Nuvolone M, et al. Among authors: kana v. PLoS One. 2017 May 17;12(5):e0177876. doi: 10.1371/journal.pone.0177876. eCollection 2017. PLoS One. 2017. PMID: 28545141 Free PMC article.

9

Transcriptional stability of cultured cells upon prion infection.

Julius C, Hutter G, Wagner U, Seeger H, Kana V, Kranich J, Klöhn PC, Weissmann C, Miele G, Aguzzi A. Julius C, et al. Among authors: kana v. J Mol Biol. 2008 Feb 1;375(5):1222-33. doi: 10.1016/j.jmb.2007.11.003. Epub 2007 Nov 12. J Mol Biol. 2008. PMID: 18082765

10

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells.

Nuvolone M, Kana V, Hutter G, Sakata D, Mortin-Toth SM, Russo G, Danska JS, Aguzzi A. Nuvolone M, et al. Among authors: kana v. J Exp Med. 2013 Nov 18;210(12):2539-52. doi: 10.1084/jem.20131274. Epub 2013 Oct 21. J Exp Med. 2013. PMID: 24145514 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page